PKW: Don't Fear The AI Bubble, Diversify With The Buyback Achievers ETF

Core Insights - The article highlights the professional background of Brendan, who has extensive experience in the pharmaceutical and biotechnology sectors, including a Ph.D. in organic synthesis from Stanford University and significant roles in major companies and startups [1]. Group 1: Professional Background - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1]. - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1]. - Brendan has experience in biotech startups, including Theravance and Aspira, before joining Caltech [1]. Group 2: Entrepreneurial Ventures - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured major investments in the eight-figure range [1]. - Brendan remains an avid investor, focusing on market trends, particularly in biotechnology stocks [1].